Key facts
- This page summarizes J. Anthony Ware's Form 4 filing for First Tracks Biotherapeutics, Inc. (TRAX).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 Sep 2026, 16:25.
J. Anthony Ware - 02 Sep 2026 Form 4 Insider Report for First Tracks Biotherapeutics, Inc. (TRAX)
- Reporting relationship
- Director
- Issuer ticker
- TRAX
- Reported as of
- 02 Sep 2026
- Net transaction value
- -$1,758,145
- SEC form
- 4
- Accepted by SEC
- 04 Sep 2026, 16:25:39 UTC
- Prior SEC filing
- 17 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ajim Tamboli, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
J. Anthony Ware filed Form 4 for First Tracks Biotherapeutics, Inc. (TRAX) on 04 Sep 2026.
Change
- Previous filing in this sequence was filed on 17 Jun 2026.
- Current net transaction value: -$1,758,145.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001715429
Primary reporting owner
Ware J. Anthony
- Relationship
- Director
- Address
- 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO
- Signature
- /s/ Ajim Tamboli, Attorney-in-Fact
- Signature date
- 04 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRAX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +39,265
- Change %
- +251%
- Price
- $5.74*
- Shares after
- 54,925
- Date
- 02 Sep 2026
- Ownership
- Direct
TRAX
transaction
Common Stock
Sale
- Transaction value
- $1,758,145
- Shares
- -39,265
- Change %
- -71%
- Price
- $44.78
- Shares after
- 15,660
- Date
- 02 Sep 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRAX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -28,571
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 28,571
- Exercise price
- $5.74
- Footnotes
- F2
TRAX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -10,694
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,694
- Exercise price
- $5.74
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.62 to $45.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The stock option is fully vested.
Footnote F3
In addition to the shares the Reporting Person owns reported in Table I, the Reporting Person also holds additional options to purchase up to an aggregate of 99,320 shares of common stock and 6,500 restricted stock units.